NR 565 FINAL EXAM – ADVANCED PHARMACOLOGY
FUNDAMENTALS
COMPREHENSIVE PRACTICE QUESTIONS WITH ANSWERS &
RATIONALES
ABOUT THIS RESOURCE
This comprehensive study guide is designed for the NR 565 Advanced Pharmacology
Fundamentals final exam at Chamberlain University. The exam covers advanced
pharmacotherapeutics for the APRN, including:
• Pharmacokinetics & Pharmacodynamics (ADME, receptor theory, dose-
response)
• Pharmacogenomics & Personalized Medicine
• Cardiovascular Pharmacology (antihypertensives, anticoagulants,
antiarrhythmics, heart failure drugs)
• Endocrine Pharmacology (diabetes, thyroid, adrenal disorders)
• Neurological & Psychiatric Pharmacology (antidepressants, antipsychotics,
antiseizure, Parkinson's)
• Antimicrobial Therapy & Stewardship
• Pain Management & Controlled Substances
• Medication Safety, Drug Interactions & Prescribing Principles
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
(Questions 1–30)
,Question 1: A patient asks how a medication taken by mouth produces an effect in the
body. The APRN explains that the process by which a drug is absorbed, distributed,
metabolized, and excreted is known as:
A) Pharmacodynamics
B) Pharmacotherapeutics
C) Pharmacokinetics
D) Pharmacogenomics
Correct Answer: C) Pharmacokinetics
Rationale: Pharmacokinetics is the study of drug movement throughout the body,
including the processes of absorption, distribution, metabolism, and excretion (ADME).
Pharmacodynamics is what the drug does to the body. Pharmacotherapeutics is the use of
drugs to treat disease. Pharmacogenomics is the study of how genes affect drug response.
Question 2: A drug that binds to a receptor and produces a response that is less than
that of a full agonist, even at maximal concentrations, is known as a:
A) Partial agonist
B) Inverse agonist
C) Competitive antagonist
D) Non-competitive antagonist
Correct Answer: A) Partial agonist
Rationale: A partial agonist has lower efficacy than a full agonist. It binds to and activates
a receptor but cannot produce a maximal response, even when all receptors are occupied.
This is an important pharmacodynamic concept for understanding drug response.
Question 3: An APRN is prescribing a medication that is known to be a CYP450 enzyme
inducer. What effect will this have on other medications metabolized by that enzyme
pathway?
A) Increased serum levels of the other medications, potentially leading to toxicity
B) Decreased serum levels of the other medications, potentially leading to therapeutic
,failure
C) No effect on serum levels of the other medications
D) Prolonged half-life of the other medications
Correct Answer: B) Decreased serum levels of the other medications, potentially
leading to therapeutic failure
Rationale: CYP450 inducers increase the metabolic activity of liver enzymes, leading to
faster breakdown of medications metabolized through that pathway. This results in
decreased serum concentrations of the "parent drug," which can lead to a loss of
therapeutic effect. Examples of inducers include carbamazepine, rifampin, phenytoin, and
phenobarbital.
Question 4: A drug with a narrow therapeutic index requires which of the following?
A) No special monitoring
B) Regular monitoring of plasma drug levels
C) Once-daily dosing only
D) Administration with a high-fat meal
Correct Answer: B) Regular monitoring of plasma drug levels
Rationale: Drugs with a narrow therapeutic index (e.g., digoxin, lithium, warfarin) have a
small margin between therapeutic and toxic doses. Close monitoring of serum levels is
essential to prevent toxicity and ensure efficacy.
Question 5: Which route of administration bypasses first-pass metabolism entirely?
A) Oral tablet
B) Sublingual
C) Intramuscular
D) Both B and C
Correct Answer: D) Both B and C (Sublingual and Intramuscular)
, Rationale: Sublingual, buccal, intravenous, intramuscular, and transdermal routes bypass
first-pass metabolism because the drug does not pass through the hepatic portal
circulation before reaching systemic circulation. Oral administration is subject to first-pass
metabolism in the liver.
Question 6: A drug that is highly protein-bound (>90%) would be expected to have:
A) A large volume of distribution
B) A small volume of distribution
C) Rapid renal elimination
D) High first-pass metabolism
Correct Answer: B) A small volume of distribution
Rationale: Highly protein-bound drugs tend to stay in the vascular compartment, resulting
in a small volume of distribution. Only the unbound (free) fraction is pharmacologically
active and can distribute to tissues.
Question 7: Which of the following factors would most significantly affect drug
absorption after oral administration?
A) Renal function
B) Hepatic blood flow
C) Gastric emptying time
D) Plasma protein binding
Correct Answer: C) Gastric emptying time
Rationale: Gastric emptying time significantly affects the rate and extent of drug
absorption. Delayed gastric emptying (e.g., from food, certain medications, or
gastrointestinal conditions) can reduce or delay drug absorption.
Question 8: The APRN explains to a patient that the "half-life" of a medication refers to:
FUNDAMENTALS
COMPREHENSIVE PRACTICE QUESTIONS WITH ANSWERS &
RATIONALES
ABOUT THIS RESOURCE
This comprehensive study guide is designed for the NR 565 Advanced Pharmacology
Fundamentals final exam at Chamberlain University. The exam covers advanced
pharmacotherapeutics for the APRN, including:
• Pharmacokinetics & Pharmacodynamics (ADME, receptor theory, dose-
response)
• Pharmacogenomics & Personalized Medicine
• Cardiovascular Pharmacology (antihypertensives, anticoagulants,
antiarrhythmics, heart failure drugs)
• Endocrine Pharmacology (diabetes, thyroid, adrenal disorders)
• Neurological & Psychiatric Pharmacology (antidepressants, antipsychotics,
antiseizure, Parkinson's)
• Antimicrobial Therapy & Stewardship
• Pain Management & Controlled Substances
• Medication Safety, Drug Interactions & Prescribing Principles
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
(Questions 1–30)
,Question 1: A patient asks how a medication taken by mouth produces an effect in the
body. The APRN explains that the process by which a drug is absorbed, distributed,
metabolized, and excreted is known as:
A) Pharmacodynamics
B) Pharmacotherapeutics
C) Pharmacokinetics
D) Pharmacogenomics
Correct Answer: C) Pharmacokinetics
Rationale: Pharmacokinetics is the study of drug movement throughout the body,
including the processes of absorption, distribution, metabolism, and excretion (ADME).
Pharmacodynamics is what the drug does to the body. Pharmacotherapeutics is the use of
drugs to treat disease. Pharmacogenomics is the study of how genes affect drug response.
Question 2: A drug that binds to a receptor and produces a response that is less than
that of a full agonist, even at maximal concentrations, is known as a:
A) Partial agonist
B) Inverse agonist
C) Competitive antagonist
D) Non-competitive antagonist
Correct Answer: A) Partial agonist
Rationale: A partial agonist has lower efficacy than a full agonist. It binds to and activates
a receptor but cannot produce a maximal response, even when all receptors are occupied.
This is an important pharmacodynamic concept for understanding drug response.
Question 3: An APRN is prescribing a medication that is known to be a CYP450 enzyme
inducer. What effect will this have on other medications metabolized by that enzyme
pathway?
A) Increased serum levels of the other medications, potentially leading to toxicity
B) Decreased serum levels of the other medications, potentially leading to therapeutic
,failure
C) No effect on serum levels of the other medications
D) Prolonged half-life of the other medications
Correct Answer: B) Decreased serum levels of the other medications, potentially
leading to therapeutic failure
Rationale: CYP450 inducers increase the metabolic activity of liver enzymes, leading to
faster breakdown of medications metabolized through that pathway. This results in
decreased serum concentrations of the "parent drug," which can lead to a loss of
therapeutic effect. Examples of inducers include carbamazepine, rifampin, phenytoin, and
phenobarbital.
Question 4: A drug with a narrow therapeutic index requires which of the following?
A) No special monitoring
B) Regular monitoring of plasma drug levels
C) Once-daily dosing only
D) Administration with a high-fat meal
Correct Answer: B) Regular monitoring of plasma drug levels
Rationale: Drugs with a narrow therapeutic index (e.g., digoxin, lithium, warfarin) have a
small margin between therapeutic and toxic doses. Close monitoring of serum levels is
essential to prevent toxicity and ensure efficacy.
Question 5: Which route of administration bypasses first-pass metabolism entirely?
A) Oral tablet
B) Sublingual
C) Intramuscular
D) Both B and C
Correct Answer: D) Both B and C (Sublingual and Intramuscular)
, Rationale: Sublingual, buccal, intravenous, intramuscular, and transdermal routes bypass
first-pass metabolism because the drug does not pass through the hepatic portal
circulation before reaching systemic circulation. Oral administration is subject to first-pass
metabolism in the liver.
Question 6: A drug that is highly protein-bound (>90%) would be expected to have:
A) A large volume of distribution
B) A small volume of distribution
C) Rapid renal elimination
D) High first-pass metabolism
Correct Answer: B) A small volume of distribution
Rationale: Highly protein-bound drugs tend to stay in the vascular compartment, resulting
in a small volume of distribution. Only the unbound (free) fraction is pharmacologically
active and can distribute to tissues.
Question 7: Which of the following factors would most significantly affect drug
absorption after oral administration?
A) Renal function
B) Hepatic blood flow
C) Gastric emptying time
D) Plasma protein binding
Correct Answer: C) Gastric emptying time
Rationale: Gastric emptying time significantly affects the rate and extent of drug
absorption. Delayed gastric emptying (e.g., from food, certain medications, or
gastrointestinal conditions) can reduce or delay drug absorption.
Question 8: The APRN explains to a patient that the "half-life" of a medication refers to:
